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Introduction
The differences between cancer and normal cells in consump-
tion and metabolism of basic nutrients have been considered a 
promising cancer therapy target for several decades (for review 
see Thompson et al., 2005; Shaw and Cantley, 2006). The me-
tabolism of glucose and glutamine has attracted a particular in-
terest, as these molecules are the main nutrients consumed by 
cancer cells. Glucose metabolism has drawn much of the atten-
tion (for review see Garber, 2006) from the time when Otto 
Warburg found that some cancer cells consume more glucose 
than normal cells and proposed that a failure to make ATP by 
oxidative phosphorylation is the cause of cancer (Warburg, 
1956). Many cancer cells indeed accumulate glucose deriva-
tives faster than normal tissues, the ability that has been used 
successfully for cancer diagnosis and monitoring (for review 
see Rohren et al., 2004).
The more recent fi ndings that glucose metabolism is 
linked to signaling pathways of cell growth and survival, and 
apoptosis in particular (for review see Hammerman et al., 2004; 
Fulda and Debatin, 2007) only reinforced the view of glucose 
metabolism as the Achilles heel of cancer cells. This view was 
also supported by the observation that depletion of glucose in-
duced apoptosis in rodent cells that were transduced with MYC, 
an oncogene that is abnormally expressed in many human can-
cers (Nesbit et al., 1999), but not in the parental cell line (Shim 
et al., 1998). This fi nding was remarkable as it suggested that 
the very processes that make cells cancerous can make cells 
dependent on glucose.
However, the idea that restricting supply of glucose or im-
itating this restriction can kill cancer cells selectively by deplet-
ing ATP is not without its critics (for review see Zu and Guppy, 
2004). Indeed, in contrast to Warburg’s proposal, both normal 
and cancer cells can produce ATP by oxidative phosphorylation, 
and the contribution of glycolysis to ATP production varies 
greatly among both normal and cancer cells. Some cancer cells 
can even survive in vitro without glucose at all if supplied with 
glutamine and nucleosides (Reitzer et al., 1979; Wice et al., 
1981; Linker et al., 1985).
Metabolism of glutamine, the major nutrient consumed by 
cancer cells besides glucose, has also been considered as a tar-
get of cancer therapy, even though with a much lower intensity 
than metabolism of glucose. The rate of glutamine transport is 
higher in cancerous than in normal cells (Bode et al., 2002), the 
activity of glutaminase, the fi rst enzyme in glutamine metabo-
lism, correlates with the growth rates of tumors (Knox et al., 
1969; Linder-Horowitz et al., 1969; Perez-Gomez et al., 2005), 
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and some cancer cell lines require glutamine or its metabolites 
for survival (for review see Medina, 2001; Fuchs and Bode, 
2006). The ability to deplete glutamine is a therapeutically rele-
vant component of asparaginase that has been used to treat acute 
lymphoblastic leukemia (Panosyan et al., 2004). Antibiotics 
DON (6-diazo-5-oxo-l-norleucine) and acivicin, which are glu-
tamine analogues, were very effective in animal models of can-
cer, perhaps due to the ability to inhibit nucleotide synthesis, 
but proved to be unacceptably toxic in clinical trials (for review 
see Ahluwalia et al., 1990).
Surprisingly, why glutamine is required for cell viability, 
or, in other words, why depletion of glutamine would kill cells, is 
not entirely clear. On the one hand, glutamine is the most abun-
dant amino acid in the body and is used by the cells in a variety 
of ways, including oxidation by the Krebs cycle to produce ATP 
(for review see Baggetto, 1992), providing nitrogen required for 
nucleotide synthesis, and being a precursor of glutathione, the 
major nonenzymatic cellular anti-oxidant (for review see Curi 
et al., 2005). However, glutamine is made by cells, which makes 
the requirement for exogenous glutamine appear unnecessary. 
Moreover, only a few percent of the consumed glutamine is used 
for macromolecular biosynthesis, while the rest is metabolized 
into molecules, such as lactate, that are released by the cells (for 
review see Newsholme et al., 1985). These observations raise the 
possibility that metabolism of glutamine not merely supports 
accelerated proliferation or an increased requirement for ATP, but 
is used for yet unrecognized pathways that are required for survival 
of cells and cancer cells in particular.
This study was designed to fi nd nutrients that are required 
for cells that express abnormally high amounts of MYC but not 
for their normal counterparts. Considering that metabolism can 
vary among species, and that human rather than animal tumors 
are of primary interest, we used human cells. To our surprise, 
we found that in contrast to rodent cells (Shim et al., 1998) glu-
cose depletion killed normal human cells irrespective of the ac-
tivity of ectopic MYC and did so not by inducing apoptosis. On 
the other hand, depletion of glutamine induced apoptosis that 
depended on activity of ectopic MYC, which led us to investi-
gate the mechanisms of this death. Overall, our study raises 
again the concern that the requirement of normal cells for glu-
cose and intraspecies differences in glucose metabolism need to 
be considered in evaluating depletion of this nutrient for thera-
peutic needs. This study also suggests that learning why cells 
require glutamine to maintain their viability may provide new 
approaches for killing cancer cells selectively.
Results
To test how an abnormally high expression of MYC affects 
the re quire ment of human cells for nutrients, we used a 
Figure 1. Glucose deprivation kills human fi broblasts by a process that is different from apoptosis and is largely unaffected by the activity of MYC. (A) IER-MYC 
cells were incubated in the presence of OHT (MYCON) or ethanol (MYCOFF) for 24 h. Media was then changed to glucose-free or to media containing 
10 mM glucose and the cells were collected at the indicated time to measure cell viability. (B) The experiment was conducted as in A except cells were col-
lected at 12 h (open bars) or 18 h (closed bars) after depletion. (C) IER-MYC cells were incubated as in A for 18 h, fi xed, stained with Hoechst 33342, and 
analyzed by fl uorescence microscopy. (D) IER-MYC fi broblasts were transduced with Bcl-2 or vector alone and incubated as in C and analyzed for cell viability 
by staining with Annexin V-FITC and propidium iodide (PI). Expression of Bcl-2 was confi rmed by immunoblotting (not depicted). The averages of three 
independent experiments are presented in B and D with the error bars representing SDs.
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well-characterized system in which MYC activity can be induced 
acutely. This system uses a fusion of MYC with a mutated hormone-
binding domain of the estrogen receptor, ERTM-MYC (Eilers et al., 
1989; Littlewood et al., 1995). ERTM-MYC is excluded from the 
nucleus, which makes the MYC moiety inactive transcription-
ally, but translocates there upon binding a synthetic estrogen an-
alogue 4-hydroxytamoxifen (OHT). We will refer to ERTM-MYC 
activated by OHT as active ERTM-MYC, and indicate active 
ERTM-MYC in the fi gures as MYCON and inactive as MYCOFF. 
This system allows studying immediate effects of MYC by mini-
mizing the artifacts associated with clonal selection of cells that 
because of additional genetic changes avoided apoptosis induced 
by ectopic expression of MYC.
To further decrease the chances of clonal selection, we 
used retroviral transduction rather than transient transfection to 
generate populations of normal human fi broblasts IMR90 that 
expressed ERTM-MYC (IER-MYC) or ERTM (IER); the latter served 
to exclude effects of OHT unrelated to MYC activity. Adding 
OHT to the tissue culture medium caused translocation of 
ERTM-MYC to the nucleus (Fig. S1 A, available at http://www
.jcb.org/cgi/content/full/jcb.200703099/DC1) and increased 
sensitivity of the cells to DNA damage (Fig. S1 B), which con-
fi rmed that the system functioned as expected (Eilers et al., 
1989; Littlewood et al., 1995).
Glucose deprivation kills normal human 
fi broblasts not by apoptosis and largely 
independently of the MYC activity
To test the system, we analyzed how induction of ERTM-MYC 
activity affects the sensitivity of the cells to depletion of glu-
cose. To our surprise, we found that in contrast to a previous 
study (Shim et al., 1998), which used rat cells transduced with 
MYC, depletion of glucose killed IER-MYC cells irrespective of 
ERTM-MYC activity (Fig. 1, A and B). The medium with 0.5 mM 
glucose, which is 2% of the normal concentration, killed the 
cells slower than a complete deficiency of the nutrient, but 
the rate was also independent of ER-Myc activity (unpublished 
data). Another difference with the report was that cells in our 
system died by a process other than apoptosis, as indicated by 
the absence of characteristic chromatin condensation (Fig. 1 C) 
and the failure of Bcl-2, an inhibitor of apoptosis, to prevent 
cell death (Fig. 1 D). These observations confi rmed a previ-
ously raised concern that glucose depletion may be toxic not 
only to cancer but also to normal cells (Zu and Guppy, 2004), 
and suggested that interspecies differences in metabolism 
should be considered in extrapolating results obtained in non-
human cells.
Glutamine deprivation induces apoptosis 
selectively in cells with acutely activated 
ER-MYC
In contrast to deprivation of glucose, depletion of glutamine 
killed IER-MYC cells faster if ERTM-MYC was active (Fig. 2 A). 
Death was associated with the activity of MYC rather with that 
of OHT or ER because IER cells remained viable in the absence 
of glutamine irrespective of the OHT treatment (Fig. S1 C). 
The IER-MYC cells died by apoptosis, as indicated by the charac-
teristic nuclear morphology of the dead cells (Fig. 2, B and C). 
Apoptosis was induced through the intrinsic pathway because 
Bcl-2 and a caspase-9 dominant-negative mutant (C9DN) pre-
vented death (Fig. 3, A and B), whereas crmA, a viral inhibi-
tor of the extrinsic pathway (Enari et al., 1995), had no effect 
(Fig. 3 D). Considering the difference in sensitivity to gluta-
mine depletion, we asked how a defi ciency in this amino acid 
Figure 2. Glutamine deprivation induces MYC-dependent apoptosis. 
(A) IER-MYC cells were incubated in the presence of OHT (MYCON) or ethanol 
(MYCOFF) for 24 h. Media was then changed to glutamine-free or to media 
containing 2 mM glutamine, and cells were collected at the indicated times 
to analyze cell viability. (B and C) IER-MYC were incubated as in A, except 
without glutamine for 18 h, fi xed, stained with Hoechst 33342, visualized 
by fl uorescence microscopy, and cells with condensed chromatin (indi-
cated by white arrows in B) were counted as apoptotic. 200 to 300 nuclei 
were counted for each sample. The averages of three independent experi-
ments are presented in A and C with errors bars indicating SD. Only MycON 
cells are shown in B.
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can kill cells and why this effect would depend on expression 
of MYC.
In principle, glutamine depletion could affect the apop-
totic machinery directly, for example by modifying molecules 
that execute apoptosis, or indirectly by causing various types of 
stress, such as DNA damage, which in turn induces activation of 
apoptosis through various pathways. The second possibility 
seemed more likely because abnormal expression of MYC sen-
sitizes cells to various agents that induce apoptosis (for review 
see Pelengaris and Khan, 2003) and because previous reports 
suggested that depletion of glutamine kills because of stress 
caused by defi ciency in proteins, ATP, glutathione, or nucleotides 
(for review see Ahluwalia et al., 1990; Fuchs and Bode, 2006). 
These explanations appeared plausible as glutamine is indeed 
used for synthesis of these molecules (Fig. 4 A) and because 
glutamine analogues DON and acivicin are thought to kill cells 
by inducing nucleotide defi ciency (Ahluwalia et al., 1990). 
Therefore we fi rst tested whether any of these explanations can 
account for MYC-dependent apoptosis in our system.
A defi ciency in protein synthesis 
or inhibition of mTOR did not cause 
apoptosis induced by glutamine depletion
A defi ciency in protein synthesis could explain apoptosis after 
glutamine depletion because glutamine is an amino acid, and 
MYC affects genes involved in protein synthesis (O’Connell et al., 
2003), which regulates cell viability (Holcik and Sonenberg, 
2005). However, omitting any of the essential amino acids from 
the tissue culture media failed to kill cells, at least over the time 
suffi cient to kill by omitting glutamine (Fig. 4 B). Therefore, 
protein synthesis was not the cause of apoptosis induced by glu-
tamine depletion.
The availability of nitrogen sources, and glutamine in par-
ticular, regulates the activity of mTOR, a kinase that controls 
protein synthesis, cell proliferation, and other processes that 
require nitrogen (for review see Sabatini, 2006). However, this 
kinase remained active in the absence of exogenous glutamine, as 
indicated by persistent phosphorylation of the mTOR target S6 
(Fig. 4 C), while the inhibitor of mTOR rapamycin caused S6 
dephosphorylation but had no effect on cell viability over the 
time suffi cient to kill cells by glutamine depletion (Fig. 4 C). 
Hence, glutamine depletion caused apoptosis by affecting path-
ways that did not require mTOR activity.
A cell cycle arrest is not the cause 
of apoptosis
One of the models that explains the ability of MYC to facili-
tate apoptosis argues that cells in which expression of MYC is 
abnormally high die because they are unable to arrest in cell 
 cycle when faced with a nutrient or growth factor defi ciency 
(for review see Pelengaris and Khan, 2003). We noticed that 
IER-MYC cells ceased to proliferate irrespective of ERTM-MYC 
activity if either any of the essential amino acids or glutamine 
were absent (unpublished data). Therefore, deregulation of cell 
cycle arrest by itself could not explain cell death caused by glu-
tamine depletion.
Apoptosis induced by glutamine depletion 
is not caused by ATP defi ciency
Several observations suggested that glutamine depletion could 
cause apoptosis by depleting ATP. Indeed, glutamine is a major 
source of ATP in rapidly dividing cells (for review see Baggetto, 
1992; Curi et al., 2005), abnormal expression of MYC acceler-
ates cell proliferation and changes metabolism of mitochondria 
(Morrish et al., 2003; Li et al., 2005), and even a transient de-
crease in ATP concentration can cause apoptosis (Izyumov 
et al., 2004; Shaw et al., 2004). To test the effects of glutamine 
depletion on ATP concentration we used IER-MYC that expressed 
C9DN (IER-MYC–C9DN), which prevents cell disassembly but not 
Figure 3. Glutamine deprivation induces apoptosis through the intrinsic 
pathway. (A) IER-MYC cells transduced with Bcl-2 or vector alone were incu-
bated in the presence of OHT (MYCON) or ethanol (MYCOFF) for 24 h, and 
then for 16 h with or without glutamine before analyzing for cell viability. 
(B) IER-MYC transduced with C9DN (IER-MYC–C9DN) or with the vector were ana-
lyzed as in A. (C) IER-MYC transduced with CrmA or vector alone were 
treated as in A except anti-Fas (α-CD95) antibody was added as indicated. 
Each graph represents averages of three independent experiments. Error 
bars indicate SD.
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the preceding steps of apoptosis (Fearnhead et al., 1998), thus 
avoiding artifacts associated with cell decomposition.  Depleting 
IER-MYC–C9DN cells of glutamine slightly decreased ATP concen-
tration (Fig. 5 A). Yet, a much larger decrease induced by a 
combination of 2-deoxyglucose, an inhibitor of glycolysis, and 
antimycin A, an inhibitor of mitochondrial respiration, failed 
to kill IER-MYC cells as effi ciently as did glutamine depletion 
(Fig. 5, A and B). Therefore, apoptosis caused by glutamine 
 depletion could not be mediated by ATP defi ciency alone. The 
observation that 2-deoxyglucose or antimycin had little effect 
on ATP concentration if used separately, but effectively decreased 
it if used together, indicated that either glycolysis or respi-
ration alone could produce suffi cient amounts of ATP in the 
cells we used.
Apoptosis is not caused 
by glutathione defi ciency
Abnormally high activity of MYC could produce suffi cient 
amounts of reactive oxygen species (ROS) to cause DNA dam-
age, genomic instability, and apoptosis (Vafa et al., 2002), per-
haps by affecting expression of mitochondrial proteins (Morrish 
et al., 2003; Li et al., 2005). MYC is also implicated in regulat-
ing concentration of glutathione (Benassi et al., 2006), the 
most abundant nonenzymatic antioxidant in the cell (Anderson 
et al., 1997). Because glutamine is a precursor of glutathione 
(Fig. 6 A), depleting this amino acid could trigger apoptosis 
by preventing inactivation of ROS. As expected, depletion of 
glutamine decreased glutathione concentration in IER-MYC–C9DN 
cells, as did l-buthionine sulfoximine (BSO), an inhibitor of 
l-glutamylcysteine synthase (Griffi th and Meister, 1979; Anderson 
et al., 1997) (Fig. 6, A and B). However, BSO failed to induce 
apoptosis in IER-MYC cells (Fig. 6 C), suggesting that glutathi-
one defi ciency alone could not be the cause of apoptosis in-
duced by glutamine depletion. This conclusion was consistent 
with our fi nding that depleting cysteine, which is required for 
glutathione synthesis (Fig. 6 A), also failed to induce apoptosis 
(Fig. 4 B), and a report that BSO failed to recapitulate apop-
tosis caused by glutamine deprivation in a hybridoma (Guerin 
et al., 2006).
Glutamine depletion does not cause 
DNA damage
Because the amido group of glutamine is used for nucleotide 
synthesis (Fig. 4 A), depletion of this amino acid could cause 
DNA damage, a well-known cause of apoptosis. Therefore, we 
tested whether glutamine depletion induces two reporters of 
DNA damage, an increase in concentration of p53 and phosphor-
ylation of histone H2AX (Rogakou et al., 1998). As expected, 
p53 concentration was induced by DON, 6-methylmercapto-
purine riboside (MMPR), an inhibitor of nucleotide synthesis 
(Stet et al., 1995), etoposide, which causes double-stranded 
DNA breaks, or by activation of ectopically expressed ERTM-
MYC (Fig. 7). In contrast, glutamine depletion not only failed 
to increase the p53 concentration, but even reversed the increase 
induced by activation of ERTM-MYC (Fig. 7). Phosphorylation 
of H2AX, as detected by immunofl uorescence, was induced by 
Figure 4. Preventing protein synthesis fails to induce apoptosis. (A) Pathways of glutamine metabolism. (B) IER-MYC cells were incubated in the pres-
ence of OHT (MYCON) for 24 h. The media was then changed to that defi cient in the indicated amino acids and the cells were incubated for 19 h 
before analyzing their viability. An average of two experiments is shown. (C) IER-MYC were incubated as in B except rapamycin was added as indi-
cated 18 h before analyzing the rate of apoptosis (top panel) and phosphorylation of S6 (bottom panels). One of two independent experiments 
is shown.
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etoposide and by activation of ERTM-MYC, but not by glutamine 
depletion (Fig. S2, available at http://www.jcb.org/cgi/content/
full/jcb.200703099/DC1). Hence, depletion of glutamine was 
unlikely to cause apoptosis by inducing DNA damage.
Apoptosis caused by glutamine depletion is 
prevented by substrates of the Krebs cycle
Because glutamine can be converted via glutamate into 2-oxo-
glutarate, a Krebs cycle intermediate (Kovacevic, 1972; Baggetto, 
1992), depletion of this amino acid could cause a defi ciency 
of this cycle. Because the Krebs cycle is not only a source of 
NADH for oxidative phosphorylation, but also a “hub” of nu-
merous metabolic pathways (http://www.tcd.ie/Biochemistry/
IUBMB-Nicholson/minimaps.html), a defi ciency in the Krebs 
cycle or its intermediates could have various consequences, 
including apoptosis, even if the normal ATP concentration is 
maintained by glycolysis (Albayrak et al., 2003; Zhou et al., 
2003). Consistent with this possibility, oxaloacetate, which is 
a membrane-permeable Krebs cycle intermediate, or pyruvate, 
which can enter the cycle by converting into acetyl-CoA or 
oxaloacetate, completely prevented apoptosis in the absence of 
glutamine (Fig. 8, A and B). However, neither pyruvate nor oxa-
loacetate restored cell proliferation (Fig. 8 C; and unpublished 
data), which suggested that the rescue was not due to replenish-
ing depleted glutamine but rather due to specifi c effect of these 
metabolites on cell viability.
Pyruvate might affect cell viability by being a substrate of 
lactate dehydrogenase (LDH), which oxidizes NADH to NAD 
(Zielke et al., 1980). Because the NADH/NAD ratio determines 
rates of many processes, from glycolysis to histone modifi ca-
tions (for review see Ladurner, 2006), affecting this ratio could 
induce apoptosis. However, the NADH/NAD ratio remained un-
changed (Fig. 8 D) and lactate was still produced (Fig. S3, avail-
able at http://www.jcb.org/cgi/content/full/jcb.200703099/DC1) 
after glutamine depletion, even though at a lower rate, indicating 
that pyruvate was unlikely to rescue from glutamine depletion by 
being a substrate of LDH.
The rescue by pyruvate and oxaloacetate could be explained 
if depletion of glutamine caused a defi ciency in the Krebs cycle. 
To test this possibility we used capillary electrophoresis coupled to 
mass spectrometry (CE-MS), an approach that estimates concen-
tration of multiple metabolites in one sample (Soga et al., 2003). 
The changes in ATP and glutathione concentrations detected by 
CE-MS refl ected those obtained by biochemical methods (Fig. 
S4 and Table S1, available at http://www.jcb.org/cgi/content/full/
jcb.200703099/DC1), indicating that the approach was reliable 
in our hands in detecting relative changes in metabolite concen-
trations. As expected, glutamine deprivation caused rapid deple-
tion of glutamate, 4-aminobutyrate, 5-oxoproline, and aspartate, 
which are products of glutamine metabolism (Fig. 9 and Table S1). 
All of the detected Krebs cycle intermediates, with the notable 
exception of citrate and isocitrate (Fig. 9), were depleted as well. 
These results indicated that glutamine depletion indeed inhib-
ited the Krebs cycle progression. Therefore, the fi ndings that the 
Krebs cycle is defi cient and the substrates of the cycle rescue 
from glutamine depletion suggested that a defi ciency in gluta-
mine causes apoptosis by affecting the Krebs cycle.
Modifi cation of nutrient requirements 
by acute activation of ectopically 
expressed MYC vary with cell type
We found that depletion of glutamine but not glucose induces 
MYC-dependent apoptosis in human cells, whereas a previous 
report indicated that glucose depletion caused MYC-dependent 
apoptosis in a rat cell line (Shim et al., 1998). This difference 
could suggest that the requirement for nutrients varies with spe-
cies and cell lines. To test this possibility, we compared several 
human cell lines that ectopically express MYC. Normal human 
foreskin fi broblasts (HFF) that express ERTM-MYC reacted to 
glutamine or glucose depletion similarly to IER-MYC (Fig. 10, 
A and B). However, human embryonic kidney epithelial cells 
immortalized by coexpression of hTERT and SV-40 large 
T antigen (HA1E) reacted to glutamine depletion as IER-MYC, but 
underwent apoptosis if depleted of glucose (Fig. 10, C and E). 
Human retinal pigmental cells (RPE) immortalized with hTERT 
(RPE-hTERT) remained alive in the absence of glutamine ir-
respective of the ectopic MYC expression, even though this 
 expression sensitized the cells to etoposide (Fig. 10 F), and died 
Figure 5. Glutamine depletion induces apoptosis not by causing ATP defi -
ciency. IER-MYC–C9DN cells (A) or IER-MYC cells (B) were incubated in the pres-
ence of OHT (MYCON) or ethanol (MYCOFF) for 24 h and then for 18 h in 
the indicated media before collecting them to measure concentration of 
ATP (A) or cell viability (B). An average of three independent experiments 
is presented in A with the error bars representing SD, and an average of 
two independent experiments in B.
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without glucose irrespective of the ectopic MYC expression by 
a mechanism that was different from apoptosis (unpublished 
data). The observed diversity was consistent with the fi nding 
that metabolism of human cells is changed by oncogenes in 
various ways (Ramanathan et al., 2005) and indicated that how 
nutrient depletion affects cancers and normal cells may be diffi -
cult to conclude by extrapolating fi ndings obtained in one or 
even a few experimental systems.
Figure 6. Depleting glutathione fails to induce apoptosis. (A) Biosynthesis of glutathione. (B) IER-MYC–C9DN were incubated with OHT (MYCON) or ethanol 
(MYCOFF) for 24 h, and then transferred to the medium depleted of glutamine or supplemented with 100 μM BSO. Cells were collected at the indicated 
time to measure reduced glutathione by fl ow cytometry (Materials and methods). (C) IER-MYC cells were treated as in A except the cells were collected at 24 h 
of incubation in the indicated media to determine the rate of apoptosis. Shown are the averages of two independent experiments.
Figure 7. Glutamine deprivation does not increase p53 concentration. IER-MYC cells were incubated in the presence of OHT (MYCON) or ethanol (MYCOFF) 
for 24 h. The cells were then incubated either in the medium that was defi cient in glutamine for 24 h, or for 36 h in the complete medium supplemented 
with DON (A), for 24 h supplemented with 1 mM MMPR (B), or for 18 h supplemented with 100 μM etoposide (C) before determining the rate of apoptosis 
(graphs) and the concentration of p53 by immunoblotting. The averages of two (A, B) or three (C) independent experiments are shown. Error bars in C 
are SDs.
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Discussion
The fi rst part of our study reiterated the previously raised con-
cern (Zu and Guppy, 2004) that the knowledge about the rela-
tive requirement of normal and transformed cells for glucose 
is still insuffi cient to make a reliable judgment as to whether 
agents that mimic glucose deprivation can be effective in cancer 
therapy. In particular, our results demonstrated that dependence 
of cells on glucose and the effects of its depletion vary among 
cell types and can depend on the combination of oncogenes ex-
pressed in these cells.
Our fi nding that a defi ciency in glutamine killed most of 
the human cells that we tested depending on the activity of 
MYC raised the possibility that the requirement for this nutrient 
can be explored for learning how to kill cancer cells in which 
MYC activity is abnormally high. Testing this possibility will 
require knowing why and how glutamine depletion kills, and 
how MYC activity synergizes with the depletion of glutamine to 
induce apoptosis.
How does glutamine depletion kill?
Several mechanisms were proposed previously to explain how 
glutamine depletion causes apoptosis, including a defi ciency in 
ATP, protein synthesis, glutathione, or nucleotides, as well as a 
change in the cellular redox state (for review see Fuchs and 
Bode, 2006). We found no evidence that any of these mecha-
nisms mediate apoptosis in our system, at least if considered 
alone. In principle, glutamine depletion could increase expres-
sion of ER-MYC, for example by stabilizing the protein, but we 
found that the concentration of this protein was unaffected by 
defi ciency in either glutamine or glucose (unpublished data).
The clue to the cause of apoptosis may be provided by 
learning how pyruvate and oxaloacetate rescue from cell death. 
Glutamine provides cells with a carbon chain, which is required 
for various synthetic activities, and amino and amido groups, 
which are required for synthesis of nucleotides and nonessential 
amino acids. Because pyruvate and oxaloacetate contain no 
nitrogen but rescue from apoptosis induced by glutamine defi -
ciency, the cause of apoptosis is likely to be associated with the 
fate of the glutamine carbon chain. This chain is the backbone 
of 2-oxoglutarate, an intermediate of the Krebs cycle. Indeed, 
our observations indicated that glutamine in our system is either 
the main source of Krebs cycle intermediates, as in some prolif-
erating normal and cancer cells  (Reitzer et al., 1979; Moreadith 
and Lehninger, 1984; Zielke et al., 1984; Kovacevic et al., 1991; 
Baggetto, 1992; Petch and Butler, 1994), or regulates the Krebs 
cycle activity.
How could a defi ciency in the Krebs cycle cause apoptosis? 
This cycle has two main functions: to supply NADH and FADH 
for oxidative phosphorylation by reducing FAD+ and NAD+ and 
Figure 8. Oxaloacetate or pyruvate rescue glutamine-depleted cells from apoptosis but not from cell cycle arrest. (A and B) IER-MYC cells were incubated in 
the presence of OHT (MYCON) or ethanol (MYCOFF) for 24 h and then in the indicated media for 18 h before measuring cell viability. An average of three 
(A) and two (B) independent experiments is presented. Error bars in A indicate SDs. (C) IER-MYC–C9DN cells were incubated with OHT for 24 h. Media was 
then changed to that containing 2 mM of the indicated supplements and incubated for 24 h in one experiment (fi lled bars) or 48 h in the second experiment 
(open bars) before counting the cells. The relative increase in cell number is shown. (D) IER-MYC–C9DN cells were treated either with ethanol or OHT and then 
incubated with or without glutamine for the indicated time before measuring the NADH to NAD+ ratio. Treatment with rotenon (Rot) was used as a posi-
tive control.
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to link multiple metabolic pathways (Fig. 9 B). Although we 
found that a defi ciency in oxidative phosphorylation does not 
cause apoptosis in our system, a change in the mitochondrial 
NADH/NAD+ and FADH/FAD+ ratios, which we did not mea-
sure, could affect other processes, including regulation of gene 
transcription (for review see Ladurner, 2006) and mitochondrial 
permeability (Jonas et al., 2004). Therefore, glutamine might 
support cell viability not by providing biosynthetic precursors, 
but by enabling the Krebs cycle to function as a catalyst of redox 
reactions (Kovacevic, 1972; Baggetto, 1992). This hypo thesis 
is consistent with the observation that only a few percent of con-
sumed glutamine is used by proliferating cells for biosynthesis 
(Newsholme et al., 1985).
Apoptosis could also be caused by a defi ciency in numer-
ous synthetic pathways that cross the Krebs cycle. For example, 
citrate is used for the synthesis of fatty acids whose defi ciency 
might change permeability of mitochondrial membranes and af-
fect their regulation by the Bcl-2 proteins (Green and Kroemer, 
2004). Some of the Krebs cycle intermediates, such as fuma-
rate, succinate, and 2-oxoglutarate, can function as messenger 
and cofactor molecules directly regulating activity of enzymes and 
thereby contributing to regulation of gene transcription and/or 
tumorigenesis (Selak et al., 2005; Chen et al., 2006). Alternatively, 
pyruvate, oxaloacetate, and other α-ketoacids could function 
as antioxidants by binding hydrogen peroxide (O’Donnell-
Tormey et al., 1987; Nath et al., 1995). This mechanism would 
imply that glutamine depletion produced some ROS or weak-
ened an antioxidant system of the cell. However, we detected 
no ROS accumulation after glutamine depletion and the anti-
oxidants that we tested, tiron and N-acetyl-cysteine, failed to rescue 
the depleted cells from apoptosis (unpublished data). Finally, 
we also cannot exclude the possibility that the cells are killed by 
a combination of the mechanisms that we tested, or that gluta-
mine metabolism has some poorly understood function whose 
effect we accidentally revealed.
How does ectopic activity of MYC 
synergize with glutamine depletion 
to induce apoptosis?
Ectopic expression of MYC makes various cells more sensitive 
to diverse stimuli that can induce apoptosis. Several hypotheses 
have been proposed to explain this sensitization (for review see 
(Adhikary and Eilers, 2005). One is that increased activity of 
MYC abrogates a DNA damage cell cycle checkpoint, thereby 
causing proliferation in the presence of unrepaired DNA breaks. 
The resulting massive DNA damage causes apoptosis. How-
ever, glutamine depletion caused cell cycle arrest irrespective of 
the ERTM-MYC activity (unpublished data), while in our hands 
depletion of essential amino acids caused cell cycle arrest but 
not apoptosis. Another hypothesis is that abnormally high ex-
pression of MYC induces the production of ROS, which have 
various deleterious effects, including DNA damage (Vafa et al., 
2002). This effect could synergize with the inhibitory effect of 
glutamine depletion on the synthesis of reduced glutathione. 
However, we detected no increase in the concentration of ROS 
or DNA damage either after activation of ERTM-MYC or deplet-
ing glutathione. Moreover, glutamine depletion even prevented 
the increase in p53 concentration caused by activation of ERTM-
MYC, which implied that in our experimental system glutamine 
metabolism links MYC activity and increase in p53 concentration. 
Figure 9. Glutamine deprivation depletes intermediates of the Krebs cycle. (A) IER-MYC–C9DN cells were incubated in the presence of OHT (MYCON) or ethanol 
(MYCOFF) for 24 h and then in the medium with or without glutamine for the indicated time. The cells were then collected at the indicated times to determine 
the concentration of intracellular metabolites by CE-MS (Materials and methods). Duplicate samples were prepared from independent plates. The result of 
one experiment is presented. The results of two more independent experiments are presented in Table S1. (B) A guide to the location of identifi ed metabo-
lites in the pathways of glutamine metabolism. The detected metabolites are indicated in red.
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One explanation of this phenomenon is that increase in p53 
concentration caused by abnormally high MYC activity is 
caused directly or indirectly by oxidative damage that is associ-
ated with a functioning respiratory chain that depends on the 
functioning Krebs cycle, but other explanations could also ac-
count for our observation and need to be explored.
Abnormally high expression of MYC might facilitate 
apoptosis by changing the expression of proteins that regulate 
apoptosis. For example, increasing the ratio of Bcl-2 proteins 
may ease permeabilization of the mitochondria after various 
kinds of stress (Maclean et al., 2003; Egle et al., 2004). Finally, 
MYC may affect multiple metabolic pathways (Osthus et al., 
2000; O’Connell et al., 2003), including concentrations of some 
mitochondrial proteins (Morrish et al., 2003; Li et al., 2005), 
thus facilitating apoptosis. Overall, how abnormal expression 
of MYC facilitates apoptosis induced by glutamine remains to 
be determined.
Relevance of glutamine metabolism 
to cancer therapy
Treatments that induce glutamine defi ciency or interfere with 
its metabolism as a substrate for nucleotide synthesis were 
highly successful in animals, but turned out to be unacceptably 
toxic in people and were largely abandoned (Ahluwalia et al., 
1990). The fi nding that the effect of glutamine depletion on cell 
viability was different both quantitatively and qualitatively from 
DON, a glutamine mimetic that was highly effective in animal 
models but toxic in people when used in the clinic (Ahluwalia 
et al., 1990), suggests that the potential of glutamine metabo-
lism as a target for cancer therapy may need revisiting. Indeed, 
we found that glutamine deprivation was much more potent 
than DON in inducing apoptosis and more selective for cells 
with ectopically activated MYC. In contrast to DON, glutamine 
depletion was not followed by an increase in p53 concentration, 
which indicated that these treatments activated different path-
ways and that glutamine deprivation may not need p53 to kill, 
which is an advantage as this protein is mutated in many can-
cers. Therefore, learning how depletion of glutamine kills cells 
may help to understand how the viability of cancer cells can 
be regulated.
Overall, our study is consistent with the view that meta-
bolic changes associated with carcinogenesis, and the energy 
metabolism in particular, might be much more complex than 
Warburg postulated, as solving even apparently simple prob-
lems, such as how a defi ciency in glutamine induces apoptosis, 
is likely to require to develop approaches that can routinely 
measure, analyze, and model the complex metabolic and signal 
transduction networks.
Materials and methods
Cell lines
Normal diploid human lung fi broblasts IMR-90 (American Type Culture 
Collection), normal diploid human foreskin fi broblasts (HFFs) (obtained 
from Donald Ganem, University of California at San Francisco, San Fran-
cisco, CA), and cell lines derived from them were maintained in DME (Invi-
trogen) without phenol red supplemented with 4.5 g/L D-glucose, 2 mM 
L-glutamine, 1 mM sodium pyruvate, 10% fetal bovine serum, and mixture 
of penicillin and streptomycin (100 g/ml each). Cells were used between 
passages 12 and 23. Human retinal epithelial RPE cells, immortalized with 
hTERT and transduced either with pMig-neo vector expressing c-MYC (RPE-
MYC) or with the vector alone, were obtained from Dun Yang (University 
of California, San Francisco) and maintained in the DMEM media 
described above. Genetically defi ned immortalized kidney epithelial 
cells (HA1E) were obtained from Robert Weinberg (Whitehead Institute, 
Figure 10. The effect of MYC on requirements for 
glutamine and glucose depends on cell type. (A) Nor-
mal human foreskin fi broblasts (HFF) transduced with 
ERTM-MYC (HFFER-MYC) were incubated with either etha-
nol (MYCOFF) or OHT (MYCON) and then with or with-
out glutamine for 48 h before scoring apoptotic nuclei. 
An average of two independent experiments is shown. 
(B) HFFER-MYC cells were incubated as in A, except the 
medium had no glucose and the viability determined 
by scoring cells stained with annexin V and PI. (C and D) 
Immortalized human kidney epithelial cells (HA1E) 
transduced with MYC-ERTM (HA1EMYC-ER) were incu-
bated and scored for apoptosis as in A either at the 
indicated time points (C) or after 24 h of glutamine 
deprivation (D). In D an average of three independent 
experiments is presented. (E) HA1EMYC-ER were treated 
and scored for viability as in B. (F) RPE-MYC and RPE-
Neo cells were incubated as indicated for 53 h before 
scoring for apoptosis. An average of three indepen-
dent experiments is shown with the error bars indicat-
ing SDs.
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Cambridge, MA). HA1E and HA1E-derived cells were grown in MEM-α 
medium (Invitrogen) supplemented with 10% fetal bovine serum and antibi-
otics as described above.
Retroviral transduction
Retroviral vectors pBABE-hygroER, expressing the estrogen receptor binding 
domain, and pBABE-hygroER-MYC expressing c-MYC fused to the estrogen 
receptor, were a gift from William Tansey (Cold Spring Harbor Laboratory, 
Cold Spring Harbor, NY). pBABE-hygroER-MYC and pBABE-puro MYC-ER 
plasmids were described previously (Eilers et al., 1989).
cDNAs encoding caspase-9 Cys287 to Ser mutant (caspase 9 domi-
nant negative, C9DN) (Fearnhead et al., 1998), crmA, Bcl-2, and human 
c-MYC were cloned into a MarX-IV-puro retroviral gene transfer vector 
(Hannon et al., 1999).
Retroviruses were produced and used to infect primary cells as de-
scribed previously (Faleiro and Lazebnik, 2000). In the case when two 
vectors were transduced, cells were infected with supernatants containing 
two different viruses simultaneously. Cells were selected with appropriate 
selection agents and obtained cell clones were pooled.
Activation of estrogen receptor fusion protein
Cells were seeded at 1.2 × 105 cells per well into 6-well plates or 5 × 104 
cells per well into 12-well plates and were allowed to attach for 7–12 h. 
ER, or the fusion of ER with MYC, were activated by adding 4-hydroxy-
tamoxifen (OHT) (Sigma-Aldrich) to the media to a fi nal concentration 
200 nM. Ethanol was used as a vehicle. Cells were washed at 24 h once 
with PBS, supplemented with fresh medium, and used for the experiments. 
Unless indicated, all media used for the experiments contained ethanol 
or OHT.
Nutrient depletion and tissue culture
To deplete glutamine or glucose, cells were cultured in glutamine or 
glucose-free DMEM that contained neither phenol red nor pyruvate (Invitro-
gen) unless indicated. When these nutrients had to be present, glucose or 
glutamine was added into the media to the fi nal concentrations, 10 mM 
and 2 mM, respectively. To prepare media defi cient in one of the essential 
amino acids, Earle’s balanced salt solution was supplemented with 4.5 g/L 
glucose (Sigma-Aldrich), MEM vitamin solution (Invitrogen), 0.37 mM 
sodium bicarbonate (Invitrogen), 24.8 μM ferric nitrate (Sigma-Aldrich), 
2 mM glutamine, and all essential amino acids, except one, at the concen-
trations of complete DMEM. Media for all experiments was supplemented 
with 10% dialyzed FBS prepared by dialyzing 50 ml of FBS against 2 liters 
of PBS using a membrane with a molecular cut-off of 3,500 D. PBS was 
changed every 12 h for 72 h.
Cell death assays
Cells were harvested by combining fl oating cells in the media with adher-
ent cells detached with 0.05% trypsin/0.53 mM EDTA solution (Invitro-
gen). Cells were washed with cold PBS, resuspended in 10 mM Hepes, 
140 mM NaCl, and 2.5 mM CaCl2, pH 7.4, and incubated with 2 μg/ml 
of recombinant annexin V conjugated to FITC for 15 min and with 4 μg/ml 
of PI for 1 min and analyzed by Becton Dickinson LSR-II cell analyzer with 
FACSVantage DiVa software. For analyzing nuclear morphology, cells 
were resuspended in staining solution containing 4% parafomaldehyde, 
50% glycerol, 0.1% Triton, and 2 μg/ml Hoechst 33342. To identify cells 
that failed to exclude Trypan Blue, the cells were collected and resus-
pended in 50 μl of PBS. The suspension was complemented with equal 
volume of 0.08% Trypan Blue solution and incubated on ice for 5 min. The 
Trypan Blue–containing cells were scored by light microscopy.
Cell cycle analysis
To analyze DNA content, 5 × 105 cells were collected by trypsinization, 
washed with PBS, fi xed with 70% ethanol (−20°C) and kept at −20°C for 
at least 4 h. After washing with PBS, cells were resuspended in PBS con-
taining 80 μg/ml RNase and 30 μg/ml PI. After incubating for 30 min at 
room temperature, samples were analyzed by LSR-II cell analyzer with 
ModFit software.
Immunofl uorescence
Cells were grown on coverslips, fi xed with 4% paraformadehyde, stained 
with appropriate primary antibody and a secondary antibody labeled with 
AlexaFluor 488, and mounted using Prolong antifade medium (Invitrogen). 
The images were taken with an Axiophot microscope (Carl Zeiss Micro-
Imaging, Inc.) with Plan-Apochromat 63×/1.40 oil objective lens, using a 
CCD camera (DFC420C; Leica) and Firecam acquisition software (Leica). 
The images were formatted using Adobe Photoshop to fi t the size of the 
fi gures. All changes in brightness or contrast, if any done, were applied to 
the entire image.
Measuring the intracellular concentration of ATP
Cells grown in 12-well plates were collected and washed with cold PBS. 
ATP was extracted by adding 1 ml of boiling water to the cell pellet as de-
scribed previously (Yang et al., 2002). The extract was vortexed and 
cleared for 5 min at 12,000 g at 4°C. 700 μl of the cleared supernatant 
were taken to measure ATP by Luciferin-Luciferase kit (Sigma-Aldrich) fol-
lowing the manufacturer’s instructions. The pellet was resuspended in the 
remaining 300 μl of the supernatant and used to determine protein con-
centration. The concentration of protein was also determined in the super-
natant used to determine ATP concentration to correct for any protein left 
after centrifugation of the extract. The amount of protein in both fractions 
was combined to obtain the total protein amount in the extract.
Measuring reduced glutathione
The amount of reduced glutathione in cells was measured by fl ow cyto-
metry as described previously (Sen et al., 1999). In brief, cells grown 
in 12-well plates were collected, resuspended in 0.5 ml of PBS containing 
1% FBS, and incubated with 40 μM monobromobimane (Biochemika) for 
10 min at room temperature. After incubation, cells were moved on ice 
and the fl uorescence at 485 nm was measured by fl ow cytometry (DiVa; 
Becton Dickinson).
Measuring the concentrations of NADH and NAD
The intracellular concentrations of NADH and NAD were measured by 
enzymatic cycling assay as described previously (Lowry et al., 1961). In 
brief, cells grown in 6-well plates were collected and washed with cold 
PBS. NADH was extracted by adding 100 μl of 0.05 N NaOH and 0.5 
mM cysteine and incubating cell suspension at 60°C for 10 min. NAD was 
extracted by adding 100 μl of 0.04 N HCl and 4 mM cysteine and incu-
bating the suspension at room temperature for 15 min. NADH and NAD 
extracts were sonicated for 30 s and used in a cycling system consisting of 
lactic dehydrogenase and glutamic dehydrogenase to produce pyruvate in 
2,000-fold yield in 30 min. Reaction was stopped by heating for 2 min at 
100°C and the concentration of pyruvate was measured using lactic dehy-
drogenase reaction fl uorimetrically. Protein was measured in the extracts 
by Bradford assay (Bio-Rad Laboratories).
Measuring concentration of lactate
Cells were grown in 12-well plates with 1 ml of media in each well. At the 
indicated time points the media was collected and pelleted at 2,000 g for 
10 min at 4°C. The supernatant was snap-frozen in liquid nitrogen and 
stored at −80°C until the assay was performed. Lactate concentration was 
measured using lactate dehydrogenase reaction (Bergmeyer, 1974).
CE-MS analysis
Metabolites were extracted from adherent cells by a procedure adopted 
from Le Belle et al. (2002). In brief, cells were collected by trypsinization, 
pelleted, and resuspended in 1 ml of cold PBS. 50 μl of cell suspension 
was taken to measure protein concentration by BCA assay (Pierce Chemi-
cal Co.). The rest of the cells were pelleted and the pellets were frozen in 
liquid nitrogen. The mixture of methanol and chloroform (−20°C) in a 2:1 
ratio (vol/vol; 360 μl/cell pellet) was added to the frozen cell pellet. The 
pellet–solvent mixture was allowed to thaw on ice and was then sonicated. 
The sonicated extracts were supplemented with internal standards, methio-
nine sulfone and Pipes (pH 7.4), at 2 nmol each. To separate hydrophilic 
and lipophylic fractions, 120 μl of chloroform and 90 μl of water were 
added. Suspension was centrifuged at 14,000 g for 20 min at 4°C. Equal 
volumes of the upper aqueous fraction were dried in a SpeedVac concen-
trator. The extracted metabolites were resuspended in 50 μl of water and 
stored at −80°C.
Extracts were analyzed by capillary-electrophoresis mass spectrom-
etry (CE-MS), according to the method devised by Soga et al. (2003) for 
the quantitation of anions in cellular extracts. Agilent CE system was inter-
faced to an Applied Biosystems QSTAR Pulsar I using Applied Biosystems’ 
CE-MS interface. Electrophoresis was performed in positively coated 110 
cm × 50 μm i.d. SMILE (+) capillary (Nacalay Tesque), using 50 mM am-
monium acetate (pH 8.5) as electrolyte. Injection was done with 50 mbar 
overpressure for 30 s; separation was carried with a constant potential of 
−30 kV. The voltage of the electrosprayer was −4.5 kV (thus reducing the 
effective electrophoresis voltage to 25.5 kV), and sheat liquid 5 mM am-
monium acetate in 50% methanol was delivered at a fl ow rate of 2 μl/min. 
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The mass spectrometer was run in full MS mode, scanning m/z 50–600 at 
3 Hz. Identifi cation was based on retention time and exact mass measure-
ments after alignment of both axes with reference compounds, and con-
fi rmed by spiked standards. For semi-quantitation, peak areas where 
normalized to that of the internal standard Pipes and to the amount of pro-
tein measured by the BCA assay. All processing steps were performed with 
custom routines written in the Matlab environment (The Mathworks).
Reagents and antibodies
Rabbit polyclonal antibodies to S6 and pS6 were obtained from Cell Sig-
naling Technology and were used in 1:1,000 and 1:4,000 dilutions, re-
spectively. Monoclonal antibody to p53, clone DO-1, was obtained from 
Calbiochem and used in 1:1,000 dilution. Anti-Fas activating antibody, 
clone CH11, was obtained from Upstate Biotechnology. Anti-pH2AX 
(Ser139) antibodies were from Upstate Biotechnology (1:1,000 dilution). 
The 9E10 antibody to Myc was obtained from the Cold Spring Harbor 
Laboratory Monoclonal Antibody Facility. Anti-actin antibodies were pur-
chased from Sigma-Aldrich. Rapamycin was obtained from Biosource Inter-
national. All other reagents were obtained from Sigma-Aldrich.
Online supplemental material
Fig. S1, A and B document that ER-MYC is activated as expected; Fig. S1 C 
demonstrates that the MYC moiety of ER-MYC makes cells sensitive to gluta-
mine depletion. Fig. S2 visualizes localization of phosphorylated histone 
H2AX in cells deprived of glutamine or treated with etoposide. Fig. S3 doc-
uments that lactate production remains largely unchanged after depletion 
of glutamine and is independent of ER-MYC activity. Fig. S4 compares the 
concentrations of glutathione and ATP measured biochemically or by mass 
spectrometry. Table S1 shows how concentrations of the measured metabo-
lites change after glutamine depletion. Online supplemental material is avail-
able at http://www.jcb.org/cgi/content/full/jcb.200703099/DC1.
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